Treatment of human papillomavirus infection in HIV-infected patients

The first reports about HIV (human immunodeficiency virus) were appeared to the 1980s. By 2017 more than 37 million people were living with HIV. Human papilloma virus (HPV) is universally spread, with some estimates showing that about 1% of the sexually active population having genital warts. Human...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: V. S. Smirnov, T. A. Kudryavtseva
Formato: article
Lenguaje:RU
Publicado: Sankt-Peterburg : NIIÈM imeni Pastera 2021
Materias:
Acceso en línea:https://doaj.org/article/01e46969b978452c853cbace7062fc58
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:01e46969b978452c853cbace7062fc58
record_format dspace
spelling oai:doaj.org-article:01e46969b978452c853cbace7062fc582021-11-22T07:09:55ZTreatment of human papillomavirus infection in HIV-infected patients2220-76192313-739810.15789/2220-7619-TOH-1233https://doaj.org/article/01e46969b978452c853cbace7062fc582021-02-01T00:00:00Zhttps://www.iimmun.ru/iimm/article/view/1233https://doaj.org/toc/2220-7619https://doaj.org/toc/2313-7398The first reports about HIV (human immunodeficiency virus) were appeared to the 1980s. By 2017 more than 37 million people were living with HIV. Human papilloma virus (HPV) is universally spread, with some estimates showing that about 1% of the sexually active population having genital warts. Human papilloma virus (HPV)-induced infection frequently accompanies the clinical course of HIV and can manifest itself in a full spectrum of clinical-pathologic forms ranging from common warts to malignant neoplasia. Due to the widespread use of antiretroviral therapy, the number of patients with a combined infection (HIV+HPV) is steadily increasing. Here we review current clinical treatment options for HPV manifestations. High-dose antiretroviral therapy does not impede HPV treatment, and can even improve its efficacy in some cases. The topical administration of imiquimod, an immune response modifier, is an effective conservative treatment in HIV-infected patients with HPV. The immunomodulation therapy of imiquimod can serve as an effective alternative of aggressive chemical and mechanical procedures. Maximum efficacy with the lowest replaces rates may be expected from combined use of mechanical ablation methods with a subsequent follow up treatment with imiqui-mod. The best therapeutic result is expected in HIV-positive patients who are received high-dose antiretroviral treatment. The advantages of Vartocid, the modified Russian equivalent of the generic imiquimod.V. S. SmirnovT. A. KudryavtsevaSankt-Peterburg : NIIÈM imeni Pasteraarticlehiv infectionhuman papillomavirus (hpv)hpv clinical manifestationstreatment methodsimiquimodaldaravartocidimmunomodulation therapyInfectious and parasitic diseasesRC109-216RUInfekciâ i Immunitet, Vol 11, Iss 1, Pp 79-84 (2021)
institution DOAJ
collection DOAJ
language RU
topic hiv infection
human papillomavirus (hpv)
hpv clinical manifestations
treatment methods
imiquimod
aldara
vartocid
immunomodulation therapy
Infectious and parasitic diseases
RC109-216
spellingShingle hiv infection
human papillomavirus (hpv)
hpv clinical manifestations
treatment methods
imiquimod
aldara
vartocid
immunomodulation therapy
Infectious and parasitic diseases
RC109-216
V. S. Smirnov
T. A. Kudryavtseva
Treatment of human papillomavirus infection in HIV-infected patients
description The first reports about HIV (human immunodeficiency virus) were appeared to the 1980s. By 2017 more than 37 million people were living with HIV. Human papilloma virus (HPV) is universally spread, with some estimates showing that about 1% of the sexually active population having genital warts. Human papilloma virus (HPV)-induced infection frequently accompanies the clinical course of HIV and can manifest itself in a full spectrum of clinical-pathologic forms ranging from common warts to malignant neoplasia. Due to the widespread use of antiretroviral therapy, the number of patients with a combined infection (HIV+HPV) is steadily increasing. Here we review current clinical treatment options for HPV manifestations. High-dose antiretroviral therapy does not impede HPV treatment, and can even improve its efficacy in some cases. The topical administration of imiquimod, an immune response modifier, is an effective conservative treatment in HIV-infected patients with HPV. The immunomodulation therapy of imiquimod can serve as an effective alternative of aggressive chemical and mechanical procedures. Maximum efficacy with the lowest replaces rates may be expected from combined use of mechanical ablation methods with a subsequent follow up treatment with imiqui-mod. The best therapeutic result is expected in HIV-positive patients who are received high-dose antiretroviral treatment. The advantages of Vartocid, the modified Russian equivalent of the generic imiquimod.
format article
author V. S. Smirnov
T. A. Kudryavtseva
author_facet V. S. Smirnov
T. A. Kudryavtseva
author_sort V. S. Smirnov
title Treatment of human papillomavirus infection in HIV-infected patients
title_short Treatment of human papillomavirus infection in HIV-infected patients
title_full Treatment of human papillomavirus infection in HIV-infected patients
title_fullStr Treatment of human papillomavirus infection in HIV-infected patients
title_full_unstemmed Treatment of human papillomavirus infection in HIV-infected patients
title_sort treatment of human papillomavirus infection in hiv-infected patients
publisher Sankt-Peterburg : NIIÈM imeni Pastera
publishDate 2021
url https://doaj.org/article/01e46969b978452c853cbace7062fc58
work_keys_str_mv AT vssmirnov treatmentofhumanpapillomavirusinfectioninhivinfectedpatients
AT takudryavtseva treatmentofhumanpapillomavirusinfectioninhivinfectedpatients
_version_ 1718417894531923968